Having established an effect for JNJ-165 as a single agent in p53 mutant CML cells, we also investigated the possibility of combining JNJ-165 with the TKIs Imatinib or PD180970 that is active against several BCR/ABL mutations [31, 32], so as to reinforce their respective antileukemic activities. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.